# US 2019/0314288 A1 · Porous polymer microspheres for preventing or treating soft tissue diseases and method for manufacturing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314288 A1
- Document ID: US20190314288A1
- Status: Published application
- Kind: A1
- Application number: 15/736,084
- Filed: 2017-05-04
- Published: 2019-10-17
- Earliest claimed: 2016-08-12
- Assignees: Korea University Research and Business Foundation; Ortho Heal Co., Ltd.
- Applicants: Korea University Research and Business Foundation; Ortho Heal Co., Ltd.
- Inventors: Hae-Ryong SONG; Jae Young LEE; Sungeun KIM; Hak Jun KIM; Young-Pil YUN
- Web page: https://patentgrep.com/patent/US20190314288A1

## CPC

- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/12: Ketones
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61L 27/44: having a macromolecular matrix
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are porous polymer microspheres for preventing or treating soft tissue diseases including a biodegradable polymer scaffold having a three-dimensional network structure in which pores having a size of 5 to 100 μm are connected to one another, and a drug for treating soft tissue diseases incorporated in the network structure of the biodegradable polymer scaffold.

## Claims

### Claim 1

Porous polymer microspheres for preventing or treating soft tissue diseases comprising:
a biodegradable polymer scaffold having a three-dimensional network structure in which pores having a size of 5 to 100 μm are connected to one another; and
a drug for treating soft tissue diseases incorporated in the network structure of the biodegradable polymer scaffold.

### Claim 2 (depends on 1)

The porous polymer microspheres according to claim 1, wherein the drug is incorporated in an amount of 2 to 30 parts by weight with respect to 10 parts by weight of the biocompatible polymer.

### Claim 3 (depends on 1)

The porous polymer microspheres according to claim 1, wherein the porous polymer microspheres have a porosity of 10 to 90% and a particle size of 200 to 1,000 μm.

### Claim 4 (depends on 1)

The porous polymer microspheres according to claim 1, wherein the porous polymer microspheres have a porosity of 60 to 90%, a pore size of 10 to 40 μm and a particle size of 200 to 500 μm.

### Claim 5 (depends on 1)

The porous polymer microspheres according to claim 1, wherein the drug for treating soft tissue diseases is selected from transforming growth factor (TGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), insulin like growth factor (IGF), bone morphogenetic protein-7 (BMP-7), anti-inflammatory peptide, aspirin, mefenamic acid, diclofenac sodium, indomethacin, naproxen, acetaminophen, ketoprofen, loxoprofen, piroxicam, ibuprofen, simvastatin, atorvastatin, fluvastatin, lovastatin, copper-peptide, prostaglandin, tramadol, celecoxib, glucosamine, chondroitin, diacerein, methotrexate, cyclosporine, an Janus Kinase 3 inhibitor (JAK-inhibitor), rituximab, tocilizumab, salazosulfapyridine (SASP), bucillamine, leflunomide, infliximab, etanercept, adalimumab, prednisolone, antiflammin 2, curcumin, sulfasalazine, lactoferrin, kartogenin, ibuprofen or a mixture thereof.

### Claim 6 (depends on 1)

The porous polymer microspheres according to claim 1, wherein the biocompatible polymer is selected from the group consisting of: any one selected from polyglycolic acid (PGA), polylactic acid (PLA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyamino acid, polylactide, polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polyhydroxyvalerate, polyhydroxybutyrate, hyaluronic acid, cellulose, heparin, collagen, alginate and chitosan; polymers blended with two or more thereof; and copolymers of two or more thereof.

### Claim 7 (depends on 1)

The porous polymer microspheres according to claim 1, wherein the soft tissue disease is selected from Achilles tendinitis, rotator cuff tendinitis, patellar tendinitis, sprains, ligamentitis, degenerative osteoarthritis and inflammatory arthritis.

### Claim 8 (depends on 1)

The porous polymer microspheres according to claim 1, wherein the porous polymer microspheres release the drug when injected in vivo.

### Claim 9 (depends on 5)

The porous polymer microspheres according to claim 5, wherein the drug for treating soft tissue diseases is kartogenin, ibuprofen, curcumin or a mixture thereof.

### Claim 10

A method for manufacturing porous polymer microspheres for preventing or treating soft tissue diseases comprising:
1) dissolving a biocompatible polymer and a drug for treating soft tissue diseases in an organic solvent to prepare a polymer solution;
2) homogenizing the polymer solution and an aqueous gelatin solution to prepare an emulsion;
3) pouring the emulsion as a discontinuous phase and a polyvinyl alcohol solution as a continuous phase into a fluidic device to produce polymer microspheres including the biocompatible polymer, the drug and gelatin; and
4) stirring the polymer microspheres in 38-50° C. water to release the gelatin from the polymer microspheres.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the drug is incorporated in an amount of 2 to 30 parts by weight with respect to 10 parts by weight of the biocompatible polymer.

### Claim 12 (depends on 10)

The method according to claim 10, wherein in homogenization, 3 to 15 parts by weight of the gelatin is added with respect to 10 parts by weight of the biocompatible polymer.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the biocompatible polymer is selected from the group consisting of: any one selected from polyglycolic acid (PGA), polylactic acid (PLA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polyamino acid, polylactide, polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polyhydroxyvalerate, polyhydroxybutyrate, hyaluronic acid, cellulose, heparin, collagen, alginate and chitosan; polymers blended with two or more thereof; and copolymers of two or more thereof.

### Claim 14 (depends on 10)

The method according to claim 10, wherein, in step 2), 0.5 to 3 parts by weight of an emulsion stabilizer is further added.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the porous polymer microspheres have a porosity of 10 to 90%, a pore size of 5 to 100 μm and a particle size of 200 to 1,000 μm.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the porous polymer microspheres have a porosity of 60 to 90%, a pore size of 10 to 40 μm and a particle size of 100 to 400 μm.

### Claim 17 (depends on 10)

The method according to claim 10, wherein the soft tissue disease is selected from Achilles tendinitis, rotator cuff tendinitis, patellar tendinitis, sprains, ligamentitis, degenerative osteoarthritis and inflammatory arthritis.

### Claim 18 (depends on 10)

The method according to claim 10, wherein, in step 2), homogenization is carried out using a homogenizer at 8,000 to 20,000 rpm for 30 seconds to 10 minutes.

### Claim 19 (depends on 10)

The method according to claim 10, wherein a release amount and rate of the drug are regulated by controlling a content of the gelatin and/or the drug with respect to a content of the biocompatible polymer.

### Claim 20 (depends on 10)

The method according to claim 10, wherein the aqueous gelatin solution is a 1 to 10 wt % aqueous gelatin solution.

### Claim 21 (depends on 10)

The method according to claim 10, wherein the discontinuous phase and the continuous phase are each poured at a flow rate of 0.2 to 1 mL/min.

### Claim 22 (depends on 10)

The method according to claim 10, wherein the organic solvent comprises one or more selected from dimethylsulfoxide, dichloromethane, tetrahydrofuran and N,N-dimethylformamide.

### Claim 23 (depends on 10)

The method according to claim 10, wherein the drug for treating soft tissue diseases is selected from transforming growth factor (TGF), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), insulin like growth factor (IGF), bone morphogenetic protein-7 (BMP-7), anti-inflammatory peptide, aspirin, mefenamic acid, diclofenac sodium, indomethacin, naproxen, acetaminophen, ketoprofen, loxoprofen, piroxicam, ibuprofen, simvastatin, atorvastatin, fluvastatin, lovastatin, copper-peptide, prostaglandin, tramadol, celecoxib, glucosamine, chondroitin, diacerein, methotrexate, cyclosporine, a Janus Kinase 3 inhibitor (JAK-3 inhibitor), rituximab, tocilizumab, salazosulfapyridine (SASP), bucillamine, leflunomide, infliximab, etanercept, adalimumab, prednisolone, antiflammin 2, curcumin, sulfasalazine, lactoferrin and kartogenin, ibuprofen or a mixture thereof.
